PCSK9 and atherosclerosis: Healthy lifestyle and lipid lowering drug (LLD) treatment is crucial in halting the progression of atherosclerotic plaque and reducing the incidence of atherosclerotic cardiovascular disease (ASCVD) events.1,2 Statins are the cornerstone drug class reducing low-density lipoprotein cholesterol (LDL-C) by more than 50%,1 Ezetimibe provides a moderate additional effect on LDL-C.3 More recently, innovative drugs targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) receptors have emerged.